Nicotine aggravates vascular adiponectin resistance via ubiquitin-mediated adiponectin receptor degradation in diabetic Apolipoprotein E knockout mouse by Gao, Jia et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Emergency Medicine Faculty 
Papers Department of Emergency Medicine 
5-18-2021 
Nicotine aggravates vascular adiponectin resistance via ubiquitin-
mediated adiponectin receptor degradation in diabetic 






See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/emfp 
 Part of the Emergency Medicine Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Emergency Medicine Faculty Papers by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Jia Gao, Jianghong Fan, Zhijun Meng, Rui Wang, Caihong Liu, Jing Liu, Bin Liang, Jing Wang, Yaoli Xie, 
Jing Zhao, Rui Guo, Jianli Zhao, Xin-Liang Ma, Xiangying Jiao, Jimin Cao, and Yajing Wang 
Gao et al. Cell Death and Disease          (2021) 12:508 
https://doi.org/10.1038/s41419-021-03772-y Cell Death & Disease
ART ICLE Open Ac ce s s
Nicotine aggravates vascular adiponectin
resistance via ubiquitin-mediated adiponectin
receptor degradation in diabetic Apolipoprotein
E knockout mouse
Jia Gao1, Jianghong Fan1, Zhijun Meng1, Rui Wang2, Caihong Liu1, Jing Liu1, Bin Liang1, Jing Wang1, Yaoli Xie1,
Jing Zhao1, Rui Guo 1, Jianli Zhao3, Xinliang Ma3, Xiangying Jiao1, Jimin Cao1 and Yajing Wang3
Abstract
There is limited and discordant evidence on the role of nicotine in diabetic vascular disease. Exacerbated endothelial cell
dysregulation in smokers with diabetes is associated with the disrupted adipose function. Adipokines possess vascular
protective, anti-inflammatory, and anti-diabetic properties. However, whether and how nicotine primes and aggravates
diabetic vascular disorders remain uncertain. In this study, we evaluated the alteration of adiponectin (APN) level in high-
fat diet (HFD) mice with nicotine (NIC) administration. The vascular pathophysiological response was evaluated with
vascular ring assay. Confocal and co-immunoprecipitation analysis were applied to identify the signal interaction and
transduction. These results indicated that the circulating APN level in nicotine-administrated diabetic Apolipoprotein E-
deficient (ApoE−/−) mice was elevated in advance of 2 weeks of diabetic ApoE−/− mice. NIC and NIC addition in HFD
groups (NIC+HFD) reduced the vascular relaxation and signaling response to APN at 6 weeks. Mechanistically, APN
receptor 1 (AdipoR1) level was decreased in NIC and further significantly reduced in NIC+HFD group at 6 weeks, while
elevated suppressor of cytokine signaling 3 (SOCS3) expression was induced by NIC and further augmented in NIC+HFD
group. Additionally, nicotine provoked SOCS3, degraded AdipoR1, and attenuated APN-activated ERK1/2 in the presence
of high glucose and high lipid (HG/HL) in human umbilical vein endothelial cells (HUVECs). MG132 (proteasome inhibitor)
administration manifested that AdipoR1 was ubiquitinated, while inhibited SOCS3 rescued the reduced AdipoR1. In
summary, this study demonstrated for the first time that nicotine primed vascular APN resistance via SOCS3-mediated
degradation of ubiquitinated AdipoR1, accelerating diabetic endothelial dysfunction. This discovery provides a potential
therapeutic target for preventing nicotine-accelerated diabetic vascular dysfunction.
Introduction
Nicotine is an important component of cigarettes and
electronic cigarettes, which has increasingly aroused
public concern about life-threatening risks1–3. New
research shows that adults who report puffing E-cigar-
ettes, or vaping, have strikingly higher odds of having a
heart attack and coronary artery disease than non-users4.
Besides, nicotine consumers with diabetes experience
more damage to the cardiovascular system than people
with diabetes alone5. Although nicotine consumers are
rarely obese, smokers with diabetes have more severe
insulin resistance than a non-smoker6–8. Therefore, the
body weight and conventional body mass index (BMI) are
inadequate to interpret diabetes in people who smoke9,10.
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There is a bulk of evidence that lipid uptake is not
related to nicotine-induced insulin resistance on smokers
with type 2 diabetes11, thus it is necessary to further study
the potential molecular mechanisms leading to the per-
sistence of insulin resistance. In addition, nicotine cessa-
tion does not stop but promotes vascular disease
development secondary to diabetes12,13. Whether and
how nicotine-induced cardiovascular system disorder
leads to and exaggerates diabetic vasculopathy needs
further clarification. Adiponectin (APN), secreted from
adipocytes, is an adipokine whose expression and plasma
levels are inversely related to obesity and insulin resis-
tance states14.
Therefore, this study aimed to access whether nicotine
causes and accelerates vasculopathy in diabetes and if so,




The animal study protocol has been approved by the
institutional animal care and used committees (IACUC)
of Shanxi Medical University. The experimental proce-
dures were in adherence with the National Institutes of
Health Guidelines on the Use of Laboratory Animals. The
adult Apolipoprotein E knockout (ApoE−/−) mice
(C57BL/6J background) were randomly divided into four
groups: normal diet (ND)-treated group; high-fat diet
(HFD, 60 kcal% fat, Cat #D12492, Research Diets, New
Brunswick, NJ, USA)-treated group; nicotine (NIC,
1.5 mg/kg/d through osmotic minipumps)/ND-treated
group and NIC+HFD-treated group (NIC+HFD).
Nicotine was purchased from Sigma-Aldrich (N-008, St.
Louis, MO, USA). Sample size was pre-determined and no
blinding was used. All groups were continuously fed with
ND or HFD for 12 weeks. Exclusion criteria of mice:
infection or death. Mice were fasted overnight and body
weight, plasma biochemical characteristics including total
cholesterol (TC), triglycerides (TG), glucose, insulin, and
APN levels were determined.
At the end of 6 and 12 weeks, the aortic segment from
the heart to iliac bifurcation was excised and cleaned,
removing adherent tissues. Vascular segments were either
homogenized for the immunoblotting assay or cut into
2–3mm vascular segments for vascular function
determination.
Aortic contractility and relaxation assay
The mouse aortic segment was quickly removed and
placed in an ice-cold Krebs-Henseleit (K-H) buffer con-
sisting of: KCl (1.752 mM), KH2PO4 (0.8165 mM),
MgSO4•7H2O (1.479 mM), NaCl (34.48 mM), NaHCO3
(1.05 mM), Dextrose (0.99 mM), and CaCl2•2H2O (0.1867
mM). Then, 2–3mm aorta rings were isometrically
mounted upon a Multi-Wire Myograph System
(DMT610M, Aarhus, Denmark). The vessel rings were
exposed to K-H buffer in the tissue bath and K-H buffer
was replaced every 15min. After equilibration and pre-
loading to 4mN, 50 μl norepinephrine (10−9 to 10−5 M)
and 50 μl acetylcholine (Ach, an endothelium-dependent
vasodilator, 10−9 to 10−4 M) were used to evaluate vessel
contractibility response. After achieving balanced states,
globular adiponectin (gAPN, 0.3, 1, 3, and 10 μg/ml) was
administered to determine APN-induced vasorelaxation
response. Globular APN was obtained from Aviscera
Bioscience (Shanghai, China). After 1 h equilibration,
acidified NaNO2 (an endothelium-independent vasodi-
lator, 10−9 to 10−4 μM, prepared by dissolving NaNO2 in
0.1 N HCl titrated to pH 2.0) was then introduced. Data
were collected and analyzed by a Power lab 8.0 system
(ADInstruments, NSW, Australia).
Biochemistry and enzyme-linked immunosorbent assay
(ELISA)
Serum samples were collected from ApoE−/− mice once
a week during the treatment with nicotine and HFD for
12 weeks. We measured fasting blood glucose (FBG), TC,
and TG on AU5800 chemistry Analyzer (Beckman
Coulter, Shanghai, China). Total APN were determined by
mouse APN ELISA kits (R&D systems, Cat #PMRP300,
Minneapolis, MN, USA). The insulin levels were deter-
mined by mouse insulin ELISA kits (ALPCO, Cat #80-
INSMS-E01, Salem, NH, USA) following the manu-
facturer’s instructions.
RNA extraction and real-time PCR
Total RNA was isolated using total RNA extraction and
purification kit (Sangon Biotech, Shanghai, China) and
then RNA concentration and purity were determined at
A260/A280 on a micro spectrophotometer (Nano-100,
Eppendorf, Shanghai, China). Real-time PCR was con-
ducted with PrimeScript™ RT reagent Kit with gDNA
Eraser (Takara, Dalian, China). Subsequently, the relative
mRNA levels were assessed using the 2−ΔΔCt method.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from the China Academy of Science (Shanghai,
China). All cell lines were authenticated by STR profiling
and routinely tested for Mycoplasma contamination. Fetal
bovine serum was obtained from CellMax (Beijing,
China). All other cell culture-related reagents were pur-
chased from Boster Biological Technology (Wuhan,
China). HUVECs were cultured in endothelial growth
medium containing 10% fetal bovine serum, 2 mM glu-
tamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Cells were randomized to receive one of the following
treatments after reaching 80% confluence: control group
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(normal glucose/normal lipid, NG/NL, the normal glu-
cose contains 5.5 mM D-glucose+ 19.5 mM L-glucose);
high glucose/high lipid group (HG/HL, 25 mM D-glu-
cose/200 μM palmitate, 24 h incubation); nicotine group
(10-7 M, 24 h incubation), and NIC+HG/HL group.
MG132 (a peptide aldehyde, potent cell-permeable pro-
teasome inhibitor, 10 µM, 6 h) was administrated to
HUVECs followed with NIC or HG/HL treatment. MG-
132 was purchased from APExBIO (Cat#A2585, Houston,
TX, USA).
Western blotting
50 μg total proteins per sample were separated by gel
electrophoresis and transferred to polyvinylidene fluoride
(PVDF) membranes followed by blocking with 5% skim-
med milk at room temperature for 1 h. Then the mem-
branes were incubated with the appropriate primary
antibodies against APN receptor 1 (AdipoR1; 1:1000
dilution, bs-0610R, Bioss, USA), suppressor of cytokine
signaling 3 (SOCS3; 1:200 dilution, sc-518020, Santa
Cruz, TX, USA), ERK1/2 (1:1000 dilution, #8544, Cell
Signaling Technology, MA, USA), Ubiquitin (1:200 dilu-
tion, P4D1, Santa Cruz, TX, USA), and β-Actin (1:1000
dilution, BM3873, Boster, Shanghai, China) at 4 °C over-
night. After washing with TBST three times, the mem-
branes were incubated with the secondary HRP-
conjugated antibody (anti-mouse or anti-rabbit antibody,
1:10,000 dilution, Boster, Shanghai, China) for 1 h. The
image was captured on ChemiDoc MP Imaging System
(Bio-Rad, CA, USA) and the density was quantified by
ImageJ (NIH).
Immunofluorescence staining assay
To detect the distribution of AdipoR1 and SOCS3 in
HUVECs, the cells after the treatment were fixed with 4%
paraformaldehyde for 15min, penetrated by 0.5% Triton
X-100 for 20min, and then blocked with goat serum.
Then the cells were incubated with anti-AdipoR1 (1:200,
bs-0610R, Bioss, Beijing, China) and anti-SOCS3 (1:200,
sc-518020, Santa Cruz, TX, USA) antibody at 4 °C over-
night. After balanced to room temperature, cells were
incubated with corresponding secondary antibody (1:100,
Boster, Shanghai, China) in the dark for 1 h. 4ʹ,6-diami-
dino-2-phenylindole (DAPI, Boster, Shanghai, China) was
used to stain the nuclei for 5 min. The cells were imaged
under a laser scanning confocal microscope (FV300,
Olympus, Tokyo, Japan).
Small interfering RNA transfection
The siRNA-SOCS3 (5ʹ-CCACAAGTGGATTCTCCTT
dTdT-3ʹ) and the non-target negative control siRNA
(Scramble) were purchased from Qiagen. Transfection
was performed using the HiPerFect transfection reagent
according to the manufacturer’s protocol. After 6–8 h of
transfection (final concentration 100 nM), the medium
was replaced by the fresh normal medium.
Co-immunoprecipitation
After treatment, HUVECs were lysed and homogenized.
The protein content of lysed cells was determined by BCA
method. Cell samples (1mg/sample) were pulled down with
2 μg anti-AdipoR1 antibody followed by the addition of
20 μl protein A+G agarose beads. Non-immune rabbit IgG
served as the negative control. The beads were extensively
washed with lysis buffer and proteins were eluted by elution
buffer and proceeded to western blot analysis.
Statistical analysis
All numerical data were presented as mean ± SD. Sta-
tistical analysis between two groups was analyzed by
Student’s t test, comparison of three or more groups using
one-way analysis of variance (ANOVA) or two-way
ANOVA followed by Tukey’s for post hoc t test. Nor-
mality of data was assessed via a Shapiro-Wilk normality
test. Homogeneity of variance test was performed. P <
0.05 was considered statistically significant. Each experi-
ment was replicated multiple time (>6). All statistical
analyses were performed via GraphPad Prism 9.0.
Results
Nicotine induced vascular APN resistance and accelerated
in ApoE−/− HFD mice
Adiponectin (APN) is a novel adipokine regarded as
“adipocyte-derived insulin”15 and it is an essential mole-
cule maintaining insulin responsiveness through activat-
ing AMPK and PPARα16,17. Since APN exerted anti-
diabetic and cardiovascular protective role18–21, and
nicotine decreased plasma APN level22,23, we speculated
that APN may be the link between nicotine and the
accelerated diabetic vascular complications.
Feeding with HFD for 12 weeks resulted in a dramatic
increase of body weight in ApoE−/− mice. Administration
of nicotine significantly decreased the body weight in ND-
fed mice and more pronounced in HFD-fed mice after
6 weeks (Supplementary Fig. 1A). However, glucose level
was discernibly increased at 4 weeks in NIC+HFD
(Supplementary Fig. 1B) compared to the HFD group.
The cholesterol and triglyceride levels in NIC+HFD
mice were increased at 6 weeks onward (Supplementary
Fig. 1C, D) compared to the HFD group. However, the
glucose, cholesterol, and triglyceride levels in NIC mice
were moderately elevated at 6 weeks compared with the
ND mice (Supplementary Fig. 1B–D). Concomitantly,
insulin resistance was appeared at 6 weeks in NIC+HFD,
whereas HFD induced insulin resistance at 8 weeks. NIC-
induced insulin resistance existed at 12 weeks compared
to ND group (Supplementary Fig. 1E). Notably, as illu-
strated in Fig. 1A, APN level was increased at 4 weeks and
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peaked at 6 weeks in NIC+HFD mice, 2 weeks earlier
than those with HFD alone. APN level in NIC mice ele-
vated and peaked at 8 weeks compared to the ND mice
(Fig. 1A).
To determine whether nicotine-induced APN resistance
impacted the vascular response, we conducted the fol-
lowing three serial experiments. Firstly, gAPN-induced
vasodilatation was assessed on aortic vascular segments
isolated from the mice treated with NIC and HFD for
6 weeks. As summarized in Fig. 1B, C, with the addition of
gAPN, there was a markedly declined vasorelaxation in
NIC+HFD-treated group compared with the HFD
group, whilst no significant difference was detected in
vasodilation induced by acidified NaNO2. In addition,
compared with ND mice, gAPN-induced vasodilation was
significantly reduced in NIC-treated mice (Fig. 1B, C).
Secondly, as it has been demonstrated that APN
receptor (AdipoR) phosphorylation may involve in the
regulation of APN sensitivity in multiple organs24, and
AdipoR1 is abundantly expressed in endothelial cells;
therefore, we further investigated the expression of Adi-
poR1 in aortic tissue. As illustrated in Fig. 1D, we found
that AdipoR1 expression was obviously reduced in NIC
treated alone compared with ND mice and further
decreased in NIC+HFD groups compared with HFD at
6 weeks, which strongly indicates that nicotine primed the
reduction of AdipoR1 level.
Thirdly, to precisely identify whether NIC modulates
AdipoR1 level in diabetic endothelial cells, HUVECs were
treated with NIC in the presence of HG/HL. As shown in
Fig. 2A, the expression of AdipoR1 was suppressed in
NIC+HG/HL compared with HG/HL group; meanwhile,
NIC treatment depressed the AdipoR1 expression com-
pared with control. APN is an upstream molecule of the
MAPK(ERK1/2) signaling axis, and MAPK(ERK1/2)
phosphorylation has been well accepted as a readout of
APN intracellular signaling18. As illustrated in Fig. 2B,
APN-induced phosphorylation of ERK1/2 was sig-
nificantly blunted after HUVECs were exposed to NIC
(10−7 M). The induced ERK1/2 activation was further
suppressed in NIC+HG/HL compared with HG/HL.
These results suggested that nicotine blocks the APN’s
signal transduction by reducing AdipoR1 level, then
blunts gAPN-induced ERK1/2 activation, contributing to
APN resistance, which was further aggravated in the
diabetic setting.
Nicotine augmented SOCS3’s expression, which was
further deteriorated in a diabetic setting
To identify how nicotine exacerbates APN resistance in
diabetic endothelial cells, we conducted qPCR array on
vascular biology profile panel to explore the possible
molecular mechanisms responsible for APN resistance.
To our surprise, among all the screened molecules,
cytokine signaling 3 (SOCS3) was the only molecule sig-
nificantly elevated by NIC and further increased in NIC+
HG/HL (Fig. 3A). To obtain more direct evidence, we
validated SOCS3 expression in aortic segments of HFD
and HFD+NIC animals. We demonstrated that an
increased tendency of SOCS3 expression in HFD animals,
but it was markedly augmented in NIC treatment and
further enhanced in NIC+HFD groups (Fig. 3B). More-
over, SOCS3 expression was significantly increased in
NIC and NIC+ HG/HL-treated HUVECs (Fig. 3C).
Finally, the immunofluorescence staining showed that
SOCS3 was co-localized with AdipoR1 in HUVECs
administrated with NIC or NIC+HG/HL, suggesting that
there is an interaction between SOCS3 and AdipoR1
(Fig. 3D).
Nicotine increased the ubiquitin-mediated degradation of
AdipoR1 through elevating SOCS3 expression
SOCS3 was involved in protein ubiquitination and
degradation25. However, whether degradation of AdipoR1
accounts for SOCS3-mediated ubiquitination and sub-
sequent degradation. More importantly, whether this
process is influenced by nicotine has not been previously
investigated. To evaluate this hypothesis, serial experi-
ments were performed.
Firstly, MG132 was administrated to evaluate the
influence of AdipoR1 degradation in HUVECs with NIC
or HG/HL treatment. We identified that MG132 blocked
NIC-induced AdipoR1 degradation and attenuated NIC+
HG/HL-induced AdipoR1 reduction; however, AdipoR1
was not influenced by MG132 when challenged with HG/
HL (Fig. 4A). These results suggested that NIC initiated
(see figure on previous page)
Fig. 1 Nicotine induced and accelerated vascular APN resistance in HFD mice. A Circulation APN level was elevated at 4 weeks and peaked at
6 weeks after nicotine treatment on HFD mice. n= 12 animals/group. *P < 0.05 vs. ND group; #P < 0.05 vs. HFD group. Data were analyzed by two-
way ANOVA. B, C. Vascular ring assay exhibited that gAPN-induced vasodilatation was significantly reduced in nicotine-treated HFD groups
compared with the HFD group. gAPN-induced vasodilatation was reduced in nicotine-treated 6 weeks group compared with the ND group.
Concentration-dependent vasorelaxation in response to acidified NaNO2 was normal. n= 12 animals/group.
*P < 0.05 vs. ND group; #P < 0.05 vs. HFD
group. Data were analyzed by two-way ANOVA. D The expression of AdipoR1 in vessels after nicotine and HFD treated for 6 weeks. n= 12 animals/
group. *P < 0.05 vs. ND group; #P < 0.05 vs. HFD group. Data were analyzed by one-way ANOVA. NIC, nicotine; HFD, high-fat diet; ND, normal diet;
gAPN, globular adiponectin.
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AdipoR1 decline and further aggravated the decrease of
AdipoR1 in HG/HL environment through ubiquitin-
mediated degradation. Secondly, in order to further
obtain evidence of interaction between SOCS3 and Adi-
poR1 in this process, we conducted the confocal co-
localization analysis and co-immunoprecipitation. Con-
focal co-localization assay revealed that nicotine pro-
moted the interaction between AdipoR1 and SOCS3 and
reinforced their interface in the circumstance of HG/HL
in endothelial cells (Fig. 4B). Meanwhile, co-
immunoprecipitation assay revealed that the interaction
between SOCS3 and AdipoR1 significantly increased in
the presence of nicotine and was aggravated in NIC+
HG/HL treatment (Fig. 4C).
SOCS3 was required for nicotine downregulation of
AdipoR1 in type 2 diabetes
To investigate whether SOCS3 is responsible for the
loss of AdipoR1 and lead to APN signaling disruption,
loss-of-function strategy was employed to identify SOCS3
role in the regulation of AdipoR1 level. As illustrated in
Fig. 5A, NIC or NIC+HG/HL-induced AdipoR1 reduc-
tion was abolished in the SOCS3 deficiency group com-
pared with the respective control. To further elaborate the
underlying mechanism, SOCS3-deficient HUVECs was
challenged by NIC or HG/HL treatment. We evaluated
the AdipoR1 ubiquitination level and the results showed
that AdipoR1 ubiquitination was markedly reduced in
SOCS3-deficient group (Fig. 5B). Furthermore, when
Fig. 2 Nicotine induced and accelerated APN resistance in diabetic endothelial cells. A The expression of AdipoR1 in HUVECs after nicotine and
HG/HL treatment. n= 6 dishes/group. *P < 0.05 vs. control group; #P < 0.05 vs. HG/HL group. Data were analyzed by one-way ANOVA. B APN-induced
ERK1/2 phosphorylation was suppressed in the presence of nicotine or HG/HL and further inhibited in nicotine combined HG/HL treatment. n= 6
dishes/group. **P < 0.01 vs. control+ gAPN group; ##P < 0.01 vs. NIC+ HG/HL+ gAPN group. Data were analyzed by two-way ANOVA. NIC, nicotine;
HFD, high-fat diet; ND, normal diet; HG/HL, high glucose/high lipid; gAPN, globular adiponectin.
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Fig. 3 (See legend on next page.)
Gao et al. Cell Death and Disease          (2021) 12:508 Page 7 of 12
Official journal of the Cell Death Differentiation Association
SOCS3 was absent, AdiopR1 and SOCS3 co-participation
levels were largely reduced in the presence of NIC+HG/
HL. These results indicated that SOCS3 is the key
molecule to mediate AdipoR1 ubiquitinoylation and then
proteosomes degrade ubiquitinated AdipoR1.
Finally, we evaluated the activation of ERK1/2 to further
clarify whether SOCS3 deficiency restored the impaired
APN signal. The results demonstrated that the inhibition
of APN-induced ERK1/2 signals was prohibited in nico-
tine or NIC+HG/HL-administrated SOCS3-deficient
HUVECs (Fig. 6A, B). These data suggested that SOCS3
is critical for nicotine-induced AdipoR1 downregulation
in diabetic conditions and responsible for the loss of APN
signaling response.
Discussion
In this study, we report a discovery that nicotine induces
vascular APN resistance, and further promotes the
development of diabetic vascular dysfunction in the HFD-
induced diabetes mice model. Nicotine upregulates E3
ligase SOCS3, which leads to AdipoR1 ubiquitination
responsible for the decrease of AdipoR1. The down-
regulation of AdipoR1 resulted in the reduction of the
signal biological response to APN, while the inhibition of
SOCS3 restores the APN response. These data indicate
that SOCS3 upregulated by nicotine is an important
contributing factor in suppressing APN sensitivity in
obesity and diabetes. Therapies aiming at inhibiting
SOCS3 in the vascular system may effectively reverse
diabetic vascular dysfunction and APN resistance in dia-
betic smokers.
In recent years, there has been a significant increase in
electronic cigarettes (nicotine as main component) which
was called a safer alternative to conventional cigar-
ettes26,27. However, E-cigarettes not only do not improve
the smoking cessation rates of traditional smokers, but
also attract young people, leading to an expansion of the
nicotine market28,29. Nicotine causes high risks in people
with cardiovascular disorders, and more impairment in
people with diabetes30,31. Diabetes accompany with
hyperadiponectinemia32. It appears much earlier than
insulin resistance33, which indicates it may play a causa-
tive role in the development of insulin resistance and
consequent distortion of diabetic vascular response. APN
resistance reduces the biologic response to APN24,34,35
and is related to APN receptor’s phosphorylation36.
However, few reports on whether and how nicotine
directly causes APN resistance leads to diabetic vascular
dysfunction. It has been reported that APN resistance
contributes to cardiovascular disease24 and precedes the
accumulation of skeletal muscle lipids and insulin resis-
tance in high-fat-fed rats33. Our findings revealed that
nicotine provoked the APN resistance in the vasculature
and further disturbed APN response in a diabetic setting,
which was demonstrated by the decrease of vasodilation
induced by APN in the diabetic ApoE−/− mice. Our study
chose ApoE−/− mice as the research mice model. Based
upon other researches and our lab’s primary results,
compared with ApoE−/− mouse37 and other mammalian
models (such as non-human primates38,39 and swine40),
the wild-type mouse (C57BL/6 J background) falls far
short of characteristics that develop morphologically
similar lesions reflecting all stages of the diabetic vascular
disease when compared to those found in humans41.
Hence, ApoE−/− are the most suitable model currently for
studying the diabetes-induced vascular injury.
Consistently with the previous report that the hor-
mone resistance accounts for alteration on receptor
level, we demonstrated that the APN receptor’s
nicotine-provoked degradation plays an important role
in APN resistance. In the present study, we further
found that the vascular response to APN was declined
in nicotine intervention group and SOCS3 was the key
regulator in mediating the downregulation of APN
receptor by ubiquitination mechanism. We also repor-
ted that the circulating APN level increased from the
4th week to peak at the 6th week, which indicated that
the increase of APN is associated with AdipoR1 ubi-
quitination. Although we observed that nicotine sig-
nificantly affects APN function in the vascular system
by inducing resistance, the contradiction of body weight
and abnormal lipid profiles in the circulation may be
related to the adipose dysfunction caused by nicotine,
inhibiting adipose expansion or proliferation.
Ubiquitin involves almost all aspects of eukaryotic
biology including protein degradation, DNA repair,
endocytosis, autophagy, transcription, immunity, and
inflammation42,43. As an E3 ubiquitin ligase, SOCS3
(see figure on previous page)
Fig. 3 SOCS3 was upregulated by NIC and further elevated in NIC combined with HG/HL treatment. A RNA profile assay showed that SOCS3
was markedly induced by NIC and further augmented with HG/HL. B Western blot validated SOCS3 upregulation in vivo mice with NIC treatment.
SOCS3 was further elevated in NIC administration on HFD mice. n= 12 animals/group. *P < 0.05 vs. ND group; ##P < 0.01 vs. HFD group. Data were
analyzed by one-way ANOVA. C The protein level of SOCS3 has verified in HUVECs with NIC or HG/HL treatment. n= 6 dishes/group. **P < 0.01 vs.
control group; ##P < 0.01 vs. HG/HL group. Data were analyzed by one-way ANOVA. D The immunofluorescence staining showed that NIC or NIC+
HG/HL induced SOCS3-AdipoR1 co-localization in HUVECs (scale bar= 100 μm). NIC, nicotine; HFD, high-fat diet; ND, normal diet; HG/HL, high
glucose/high lipid.
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Fig. 4 Nicotine increased the ubiquitin-mediated AdipoR1 degradation via SOCS3. A MG132 partially reversed NIC+ HG/HL-induced AdipoR1
reduction. n= 6 dishes/group. **P < 0.01 vs. NIC group; ##P < 0.05 vs. NIC+ HG/HL group. Data were analyzed by two-way ANOVA. B
Immunofluorescence assay showed that NIC or HG/HL-promoted AdipoR1 degradation was blocked by MG132 in HUVECs (scale bar= 50 μm). C The
interaction between SOCS3 and ubiquitinated AdipoR1 was evidenced by co-immunoprecipitation assay. n= 6 dishes/group. **P < 0.01 vs. control+
MG132 group; ##P < 0.05 vs. HG/HL+MG132 group. Data were analyzed by one-way ANOVA. NIC, nicotine; HG/HL, high glucose/high lipid; UbiR1,
ubiquitinated AdipoR1.
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Fig. 5 SOCS3 was required for nicotine-induced AdipoR1 downregulation in diabetes. A SOCS3 deficiency restored AdipoR1 level that was
suppressed by nicotine or NIC+HG/HL. Top, the western blot showed the protein levels of AdipoR1 and SOCS3. β-Actin as internal references. Bottom,
quantification of the density of western panel. n= 6 dishes/group. **P < 0.01 vs. NIC group; ##P < 0.05 vs. NIC+HG/HL group. Data were analyzed by two-
way ANOVA. B SOCS3 deficiency abolished AdipoR1 ubiquitination induced by nicotine or HG/HL. Top, co-immunoprecipitation showed the protein level
of ubiquitinated AdipoR1 and SOCS3. Bottom, quantification of the density of western panel. n= 6 dishes/group. **P < 0.01 vs. NIC group; ##P < 0.05 vs.
NIC+HG/HL group. Data were analyzed by two-way ANOVA. NIC, nicotine; HG/HL, high glucose/high lipid; UbiR1, ubiquitinated AdipoR1.
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targets associated proteins for proteasomal degradation44.
Our study identified that nicotine upregulates SOCS3
expression, promoting the interaction between AdipoR1
and SOCS3, leading to AdipoR1 ubiquitination, whereas
the SOCS3 inhibition restores AdipoR1 degradation, and
reverse the corresponding AdipoR1 signals. In addition,
our research shows that AdipoR1 ubiquitination hinders
APN signaling, which is evidenced by the inhibition of
ERK1/2 activation, a conventional signaling pathway
activated by APN. However, there are still many unre-
solved questions that warrant further investigation. The
mechanism by which nicotine increases SOCS3 is in great
need to be explored.
In summary, our study identified that nicotine-
provoked SOCS3-mediated AdipoR1 ubiquitination is a
key mechanism of APN resistance in diabetes with nico-
tine. These findings help explain the general phenomenon
of the accelerated development of diabetes in smokers,
and may also help us understand that inhibiting AdipoR1
ubiquitination as a novel therapeutic target holds promise
to prevent nicotine-induced diabetic endothelial
dysfunction.
Supplementary information is available at Cell Death &
Disease’s website.
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